Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3–10. https://doi.org/10.1016/j.ejim.2023.11.005[publishedOnlineFirst:2023/11/09] .
Article CAS PubMed Google Scholar
Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translat Gastroenterol Hepatol 2020;5:16. https://doi.org/10.21037/tgh.2019.09.08[publishedOnlineFirst:2020/04/08] .
Article PubMed PubMed Central Google Scholar
Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, MD). 2023;77(4):1335–47. https://doi.org/10.1097/hep.0000000000000004[publishedOnlineFirst:2023/01/11] .
Mann JP, Valenti l, scorletti e, et al. nonalcoholic fatty liver disease in children. Sem Liver Disease 2018;38(1):1–13. https://doi.org/10.1055/s-0038-1627456 [published Online First: 2018/02/23]
Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841–50. https://doi.org/10.3350/cmh.2022.0239[publishedOnlineFirst:2022/09/20] .
Article PubMed PubMed Central Google Scholar
Hosseini Shabanan S, Martins VF, Wolfson T, et al. MASLD: what we have learned and where we need to go-a call to action. Radiographics : Rev Publ Radiological Soc North Am, Inc 2024;44(11):e240048. https://doi.org/10.1148/rg.240048 [published Online First: 2024/10/18]
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18(4):223–38. https://doi.org/10.1038/s41575-020-00381-6[publishedOnlineFirst:2020/12/23] .
Barone M, Martucci M, Sciara G, et al. Towards a personalized prediction, prevention and therapy of insomnia: gut microbiota profile can discriminate between paradoxical and objective insomnia in post-menopausal women. EPMA J. 2024;15(3):471–89. https://doi.org/10.1007/s13167-024-00369-1[publishedOnlineFirst:2024/09/06] .
Article PubMed PubMed Central Google Scholar
Ratziu V, Friedman SL. Why do so many nonalcoholic steatohepatitis trials fail? Gastroenterology. 2023;165(1):5–10. https://doi.org/10.1053/j.gastro.2020.05.046[publishedOnlineFirst:2020/05/23] .
Kobayashi T, Iwaki M, Nakajima A, et al. Current research on the pathogenesis of NAFLD/NASH and the gut-liver axis: gut microbiota, dysbiosis, and leaky-gut syndrome. Int J Mol Sci 2022;23(19) https://doi.org/10.3390/ijms231911689 [published Online First: 2022/10/15]
Alisi A, McCaughan G, Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact. Hep Intl 2024;18(Suppl 2):861–72. https://doi.org/10.1007/s12072-024-10674-6[publishedOnlineFirst:2024/07/12] .
Wang H, Guo Y, Han W, et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. J Agric Food Chem 2024;72(36):20194–210. https://doi.org/10.1021/acs.jafc.4c04630[publishedOnlineFirst:2024/08/28] .
Article CAS PubMed Google Scholar
Ross FC, Patangia D, Grimaud G, et al. The interplay between diet and the gut microbiome: implications for health and disease. Nat Rev Microbiol 2024;22(11):671–86. https://doi.org/10.1038/s41579-024-01068-4[publishedOnlineFirst:2024/07/16] .
Article CAS PubMed Google Scholar
Segata N. Gut microbiome: westernization and the disappearance of intestinal diversity. Curr Biol : CB 2015;25(14):R611–3. https://doi.org/10.1016/j.cub.2015.05.040[publishedOnlineFirst:2015/07/22] .
Article CAS PubMed Google Scholar
Van Hul M, Cani PD, Petitfils C, et al. What defines a healthy gut microbiome? Gut 2024;73(11):1893–908. https://doi.org/10.1136/gutjnl-2024-333378[publishedOnlineFirst:2024/09/26] .
Article CAS PubMed Google Scholar
Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 2015;1(2):222–32. https://doi.org/10.1016/j.jcmgh.2015.01.001[publishedOnlineFirst:2015/09/26] .
Article PubMed PubMed Central Google Scholar
Saeed H, Díaz LA, Gil-Gómez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2024. https://doi.org/10.3350/cmh.2024.0811[publishedOnlineFirst:2024/11/28] .
Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH. EMBO Mol Med 2019;11(2) https://doi.org/10.15252/emmm.201809302 [published Online First: 2018/12/29]
Basil B, Myke-Mbata BK, Eze OE, et al. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol 2024;10(1):39. https://doi.org/10.1186/s40842-024-00187-4[publishedOnlineFirst:2024/12/02] .
Article PubMed PubMed Central Google Scholar
Gäbele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011;55(6):1391–9. https://doi.org/10.1016/j.jhep.2011.02.035[publishedOnlineFirst:2011/06/28] .
Article CAS PubMed Google Scholar
Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 2016;151(4):733-46.e12. https://doi.org/10.1053/j.gastro.2016.06.022[publishedOnlineFirst:2016/06/28] .
Article CAS PubMed Google Scholar
Negi CK, Babica P, Bajard L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metab: Clin Exp 2022;126:154925. https://doi.org/10.1016/j.metabol.2021.154925 [published Online First: 2021/11/07]
Mohamad Nor MH, Ayob N, Mokhtar NM, et al. The effect of probiotics (MCP(®) BCMC(®) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients 2021;13(9) https://doi.org/10.3390/nu13093192 [published Online First: 2021/09/29]
Gkiourtzis Ν, Kalopitas G, Vadarlis A, et al. The benefit of probiotics in pediatric nonalcoholic fatty liver disease: a meta-analysis of randomized control trials. J Pediatr Gastroenterol Nutr 2022;75(3):e31–7. https://doi.org/10.1097/mpg.0000000000003537[publishedOnlineFirst:2022/06/28] .
Konieczna J, Fiol M, Colom A, et al. Does consumption of ultra-processed foods matter for liver health? Prospective analysis among older adults with metabolic syndrome. Nutrients 2022;14(19) https://doi.org/10.3390/nu14194142 [published Online First: 2022/10/15]
Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11(8):506–14. https://doi.org/10.1038/nrgastro.2014.66 [published Online First: 2014/06/11]
Wen X, Liu H, Luo X, et al. Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats. Front Microbiol 2023;14:1146672. https://doi.org/10.3389/fmicb.2023.1146672[publishedOnlineFirst:2023/06/02] .
Article PubMed PubMed Central Google Scholar
O’Callaghan A, van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 2016;7:925. https://doi.org/10.3389/fmicb.2016.00925[publishedOnlineFirst:2016/07/06] .
Article PubMed PubMed Central Google Scholar
Lu J, Shataer D, Yan H, et al. Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity. Foods (Basel, Switzerland) 2024;13(18) https://doi.org/10.3390/foods13182992 [published Online First: 2024/09/28 22:45]
Holmberg SM, Feeney RH, Prasoodanan PKV, et al. The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids. Nat Commun 2024;15(1):3502. https://doi.org/10.1038/s41467-024-47594-w[publishedOnlineFirst:2024/04/26] .
Article CAS PubMed PubMed Central Google Scholar
Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75[publishedOnlineFirst:2017/06/15] .
Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–8. https://doi.org/10.1017/s0007114517000204[publishedOnlineFirst:2017/03/28] .
Article CAS PubMed Google Scholar
Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–53. https://doi.org/10.1007/s10620-011-1887-4[publishedOnlineFirst:2011/09/09] .
Bomhof MR, Parnell JA, Ramay HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019;58(4):1735–45. https://doi.org/10.1007/s00394-018-1721-2[publishedOnlineFirst:2018/05/21] .
Article CAS PubMed Google Scholar
Gu YJ, Chen LM, Gu ME, et al. Body mass index-based predictions and personalized clinical strategies for colorectal cancer in the context of PPPM. EPMA J. 2022;13(4):615–32. https://doi.org/10.1007/s13167-022-00306-0. [publishedOnlineFirst:2022/12/13].
Comments (0)